Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP)

Clinical and Experimental Immunology

Volumn 162, Issue 3, 2010, Pages 415-424

  Machino, Y ^a   Ohta, H ^a   Suzuki, E ^a   Higurashi, S ^a   Tezuka, T ^a   Nagashima, H ^a   Kohroki, J ^a   Masuho, Y ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Fc receptors; Idiopathic thrombocytopaenia purpuria thrombocytopenia; Intravenous immunoglobulin therapy; Platelets; Protein structure folding

Indexed keywords

BLOCKING ANTIBODY; CD16 ANTIGEN; FC RECEPTOR; FC RECEPTOR IIA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; RECOMBINANT PROTEIN; SULFONATED IMMUNOGLOBULIN; IGG, SULFONATED; IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISULFIDE BOND; DRUG EFFECT; DRUG EFFICACY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ALKYLATION; ANIMAL; ANTIBODY AFFINITY; BAGG ALBINO MOUSE; CHEMISTRY; DISEASE COURSE; DISEASE MODEL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ALKYLATION; ANIMALS; ANTIBODY AFFINITY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG; TREATMENT OUTCOME;

EID: 79952471213     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04255.x     Document Type: Article

References (36)

1. Lemieux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005; 42:839-48.
2. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-31.
3. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-55.
4. 2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9:431-8.
5. Debré M, Bonnet MC, Fridman WH et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342:945-9.
6. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484-6.
7. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002; 2:580-92.
8. Teeling JL, Jansen-Hendriks T, Kuijpers TW et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98:1095-9.
9. van Mirre E, Teeling JL, van der Meer JW, Bleeker WK, Hack CE. Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcγRII and FcγRIIIb. J Immunol 2004; 173:332-9.
10. Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev 2008; 22:103-16.
11. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005; 310:1510-12.
12. Konrad S, Baumann U, Schmidt RE, Gessner JE. Intravenous immunoglobulin (IVIG)-mediated neutralization of C5a: a direct mechanism of IVIG in the maintenance of a high FcγRIIB to FcγRIII expression ratio on macrophages. Br J Haematol 2006; 134:340-50.
13. Masuho Y, Tomibe K, Matsuzawa K, Ohtsu A. Development of an intravenous γ-globulin with Fc activities: I. Preparation and characterization of S-sulfonated human γ-globulin. Vox Sang 1977; 32:175-81.
14. Schreiber JR, Barrus VA, Siber GR. Decreased protective efficacy of reduced and alkylated human immune serum globulin in experimental infection with Haemophilus influenzae type b. Infect Immun 1985; 47:142-8.
15. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 2006; 177:1129-38.
16. Yamanaka T, Abo W, Chiba S et al. Clinical effect and metabolism of S-sulfonated immunoglobulin in 7 patients with congenital humoral immunodeficiency. Vox Sang 1979; 37:14-20.
17. Masuho Y, Tomibe K, Watanabe T, Fukumoto Y. Development of an intravenous g-globulin with Fc activities: II. Reconversion of S-sulfonated human g-globulin into the original g-globulin. Vox Sang 1977; 32:290-5.
18. Nagashima H, Tezuka T, Tsuchida W, Maeda H, Kohroki J, Masuho Y. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcg receptors, resulting in enhanced antibody-dependent cellular cytotoxicity. Mol Immunol 2008; 45:2752-63.
19. Ghetie M-A, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA 1997; 94:7509-14.
20. Medgyesi D, Uray K, Sallai K et al. Functional mapping of the FcγlRII binding site on human IgG1 by synthetic peptides. EurJ Immunol 2004; 34:1127-35.
21. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcγ receptor in complex with Fc. J Biol Chem 2001; 276:16469-77.
22. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 2000; 406:267-73.
23. Seegan GW, Smith CA, Schumaker VN. Changes in quaternary structure of IgG upon reduction of the inter heavy-chain disulfide bond. Proc Natl Acad Sci USA 1979; 76:907-11.
24. Ghirlando R, Keown MB, Mackay GA, Lewis MS, Unkeless JC, Gould HJ. Stoichiometry and thermodynamics of the interaction between the Fc fragment of human IgG1 and its low-affinity receptor FcγRIII. Biochemistry 1995; 34:13320-7.
25. Sondermann P, Jacob U, Kutscher C, Frey J. Characterization and crystallization of soluble human Fcγ receptor II (CD32) isoforms produced in insect cells. Biochemistry 1999; 38:8469-77.
26. Shields RL, Lai J, Keck R et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40.
27. Matsumiya S, Yamaguchi Y, Saito J et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 2007; 368:767-79.
28. Bazin R, Lemieux R, Tremblay T. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 2006; 135:97-100.
29. Tridandapani S, Siefker K, Teillaud JL, Carter JE, Wewers MD, Anderson CL. Regulated expression and inhibitory function of FcγRIIb in human monocytic cells. J Biol Chem 2002; 277:5082-9.
30. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fcg Fce functional fusion protein inhibits FcγRI-mediated degranulation. Nat Med 2002; 8:518-21.
31. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001; 115:679-86.
32. Boruchov AM, Heller G, Veri M-C, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005; 115:2914-23.
33. Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells. Nat Med 2006; 12:688-92.
34. Park-Min KH, Serbina NV, Yang W et al. FcγRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007; 26:67-78.
35. Uchino H, Yasunaga K, Akatsuka J. A cooperative clinical trial of high-dose immunoglobulin therapy in 177 cases of idiopathic thrombocytopenic purpura. Thromb Haemost 1984; 30:182-5.
36. 2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology 1997; 90:212-18.